{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:44:39Z","timestamp":1775673879851,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background and Purpose:<\/jats:bold> Natalizumab is a highly efficacious disease-modifying therapy for relapsing-remitting multiple sclerosis (MS). Data on the efficacy and safety profile of natalizumab in Asian patients with MS are limited. This study assessed the efficacy and safety of natalizumab in Korean patients with MS in a real-world setting.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study enrolled consecutive Korean patients with active relapsing-remitting MS who were treated with natalizumab for at least 6 months between 2015 and 2021. To evaluate the therapeutic outcome of natalizumab, we used the Expanded Disability Status Scale (EDSS) scores and brain magnetic resonance imaging; adverse events were assessed at regular intervals. No evidence of disease activity (NEDA) was defined as no clinical relapse, no worsening of EDSS score, and no radiological activities.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Fourteen subjects with MS were included in the study. The mean age at initiation of natalizumab therapy was 32 years. All patients were positive for anti-John Cunningham virus antibodies before natalizumab administration. The mean annual relapse rate was markedly reduced from 2.7 \u00b1 3.2 before natalizumab therapy to 0.1 \u00b1 0.4 during natalizumab therapy (<jats:italic>p<\/jats:italic> = 0.001). Disability was either improved or stabilized after natalizumab treatment in 13 patients (93%). During the 1st year and 2 years after initiating natalizumab, NEDA-3 was achieved in 11\/12 (92%) and 9\/11 (82%) patients, respectively. No progressive multifocal leukoencephalopathy or other serious adverse events leading to the discontinuation of natalizumab were observed.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Natalizumab therapy showed high efficacy in treating Korean patients with active MS, without unexpected safety problems.<\/jats:p>","DOI":"10.3389\/fneur.2021.714941","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:38:23Z","timestamp":1625737103000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Ki Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Won","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0050-3","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrd1752","article-title":"Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab","volume":"4","author":"Steinman","year":"2005","journal-title":"Nat Rev Drug Discov."},{"key":"B3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/imt-2016-0113","article-title":"Natalizumab treatment of multiple sclerosis: new insights","volume":"9","author":"Delbue","year":"2017","journal-title":"Immunotherapy."},{"key":"B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3988\/jcn.2020.16.3.355","article-title":"Monoclonal antibody therapies for multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"16","author":"Kim","year":"2020","journal-title":"J Clin Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the tysabri observational program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-021-10559-w.","article-title":"Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the austrian MS treatment registry","author":"Guger","year":"2021","journal-title":"J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00415-018-8813-z","article-title":"Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration","volume":"265","author":"Aoyama","year":"2018","journal-title":"J Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3988\/jcn.2019.15.4.454","article-title":"High seroprevalence and index of anti-john-cunningham virus antibodies in korean patients with multiple sclerosis","volume":"15","author":"Kim","year":"2019","journal-title":"J Clin Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2055217318788699","DOI":"10.1177\/2055217318788699","article-title":"High prevalence and indexes of anti-john cunningham virus antibodies in a cohort of chinese patients with multiple sclerosis","volume":"4","author":"Lau","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40120-016-0062-4","article-title":"Natalizumab for achieving relapse-free, T1 gadolinium-enhancing-lesion-free, and T2 lesion-free status in Japanese multiple sclerosis patients: a phase 2 trial subanalysis","volume":"6","author":"Saida","year":"2017","journal-title":"Neurol Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40120-016-0059-z","article-title":"Safety and efficacy of natalizumab in japanese patients with relapsing-remitting multiple sclerosis: open-label extension study of a phase 2 trial","volume":"6","author":"Saida","year":"2017","journal-title":"Neurol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the mcdonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"102311","DOI":"10.1016\/j.msard.2020.102311","article-title":"Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. study of two high-dose methylprednisolone schedules","volume":"44","author":"Fuentes-Rum\u00ed","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.autrev.2018.09.012","article-title":"A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis","volume":"18","author":"Sellner","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clineuro.2016.07.001","article-title":"Effectiveness and safety of natalizumab in real-world clinical practice: review of observational studies","volume":"149","author":"van","year":"2016","journal-title":"Clin Neurol Neurosurg."},{"key":"B20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","article-title":"Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY)","volume":"22","author":"Cohan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00415-016-8162-8","article-title":"Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors","volume":"263","author":"Zurawski","year":"2016","journal-title":"J Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2055217318824618","DOI":"10.1177\/2055217318824618","article-title":"Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy","volume":"5","author":"Cohan","year":"2019","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1007\/s00415-019-09464-0","article-title":"Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the austrian ms treatment registry","volume":"266","author":"Guger","year":"2019","journal-title":"J Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/practneurol-2015-001355","article-title":"Switching patients at high risk of pml from natalizumab to another disease-modifying therapy","volume":"16","author":"Giovannoni","year":"2016","journal-title":"Pract Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/1352458517726381","article-title":"Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients","volume":"24","author":"Leurs","year":"2018","journal-title":"Mult Scler."},{"key":"B28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis","year":"2016","journal-title":"J Neurol, Neurosurg Psychiatr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated pml in patients with ms is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical Outcomes of Escalation vs. Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA."},{"key":"B33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.msard.2017.07.003","article-title":"Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?","volume":"17","author":"Fern\u00e1ndez","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40263-020-00716-6","article-title":"Changes in anti-JCV antibody status in a large population of multiple sclerosis patients treated with natalizumab","volume":"34","author":"Sgarlata","year":"2020","journal-title":"CNS Drugs."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.714941\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:38:25Z","timestamp":1625737105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.714941\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":34,"alternative-id":["10.3389\/fneur.2021.714941"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.714941","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"article-number":"714941"}}